secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADIAL PHARMACEUTICALS, INC. (ADIL)
CIK:        0001513525
Form:       8-K
Filed at:   2025-12-01T23:59:59+00:00
Accession:  0001213900-25-116666
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adial Pharmaceuticals raises $2.86M via warrant inducement; issues new Series F warrants for up to 13.8M shares
--------------------------------------------------------------------------------

- Holder exercised 9,215,675 existing Series C-1 and E warrants at $0.31/share, generating gross proceeds of $2.86M.
- In consideration, company issued new unregistered Series F warrants to purchase up to 13,823,512 shares at $0.31.
- New warrants exercisable only after stockholder approval, term 24 months from approval date; company must seek approval within 120 days of closing.
- Company agreed to 60-day standstill on equity issuances (except ATM after 31 days) and 6-month no variable rate transactions.
- A.G.P./Alliance Global Partners acted as financial advisor with an 8% fee on gross proceeds.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1513525/000121390025116666/0001213900-25-116666-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1513525/000121390025116666/ea0267799-8k_adial.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-116666

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer